<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911285</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00052757</org_study_id>
    <nct_id>NCT02911285</nct_id>
  </id_info>
  <brief_title>NAC for Treating Comorbid PTSD and SUD</brief_title>
  <acronym>DoD-NAC</acronym>
  <official_title>Glial Regulators for Treating Comorbid Posttraumatic Stress Disorder and Substance Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Translational Neuroscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As a result of sustained operations in Afghanistan and Iraq, there are an increasing number&#xD;
      of U.S. military Veterans with substance use disorders and comorbid posttraumatic stress&#xD;
      disorder (PTSD). If left untreated, individuals with substance use disorders and PTSD are at&#xD;
      increased risk for developing other mental health problems (e.g., depression, anxiety),&#xD;
      suicidal ideation and attempts, medical problems, reduced resiliency and military readiness,&#xD;
      vocational problems, and family/social impairment. This study will determine the benefits of&#xD;
      N-acetylcysteine (NAC) in treating alcohol use disorder and comorbid post-traumatic stress&#xD;
      disorder (PTSD) among military Veterans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a result of sustained operations in Afghanistan and Iraq, there are an increasing number&#xD;
      of U.S. military Veterans with substance use disorders and comorbid posttraumatic stress&#xD;
      disorder (PTSD). While mental health services are in place for U.S. service members,&#xD;
      substantial gaps in the treatment of co-occurring substance use disorders and PTSD exist and&#xD;
      there is little scientific evidence available to guide the provision of care. Treatment for&#xD;
      comorbid substance use disorders and PTSD, especially pharmacologic treatment, is largely&#xD;
      ineffective and short-lived. While there have been numerous studies focused largely on&#xD;
      dopaminergic mechanisms of reward, they have not led to the development of adequate&#xD;
      treatments for comorbid substance use disorders and PTSD. Animal models demonstrate that (a)&#xD;
      acute stress and chronic use of addictive substances reduce the capacity of glia to remove&#xD;
      the neurotransmitter glutamate, and (b) this impairment as well as relapse can be prevented&#xD;
      or reversed by N-acetylcysteine (NAC). Further, human studies indicate that NAC is associated&#xD;
      with reduced craving and substance use. Based on this, the investigators conducted a Proof of&#xD;
      Principle (PoP) study which was the first to examine the use of NAC for the treatment of&#xD;
      PTSD, with or without comorbid addiction. In this randomized, controlled double-blind pilot&#xD;
      study the investigators showed that Veterans with substance use disorders (81.5% alcohol use&#xD;
      disorder) and PTSD who were treated with 2400mg NAC for 8 weeks demonstrated significant&#xD;
      reduction in PTSD severity and craving. Moreover, reductions in PTSD and substance-related&#xD;
      symptomatology were sustained at 1-month follow-up. However, to extend and confirm its&#xD;
      clinical utility in the military/Veteran context, it is important to know whether NAC reduces&#xD;
      severity of alcohol use disorder (AUD), the most common addiction among Veterans and military&#xD;
      service members, and the mechanisms underlying therapeutic response. Based on promising data&#xD;
      from the PoP project, the proposed Extend-and-Confirm (EC) study will determine the efficacy&#xD;
      of NAC in reducing AUD and comorbid PTSD in Veterans (N=90). Further, new aims include the&#xD;
      application of functional magnetic resonance imaging (fMRI) and proton magnetic resonance&#xD;
      spectroscopy (1H-MRS) to investigate the pathophysiology of AUD/PTSD, as well as prognostic&#xD;
      indicators of treatment outcome. These aims extend the Future Plans proposed in the original&#xD;
      PoP study and provide an opportunity for collaboration among clinical and preclinical&#xD;
      investigators at the Ralph H. Johnson Veterans Affairs (VA) Medical Center and the Medical&#xD;
      University of South Carolina (MUSC) to solve this critical health problem in the military&#xD;
      context. In the proposed EC study, the investigators will (1) employ a randomized,&#xD;
      double-blind, between-groups experimental design that will consist of 8 weeks of treatment&#xD;
      with NAC (2400mg) or placebo medication, and follow-up assessment at 1-, 3-, and 6-months&#xD;
      post treatment; (2) use standardized, repeated dependent measures to rigorously assess AUD&#xD;
      severity and PTSD symptomatology during treatment and follow-up; (3) collect biologic&#xD;
      measures of alcohol use; (4) measure impairment in associated areas of functioning (e.g.,&#xD;
      depression, sleep, suicidality, risky sexual behaviors, family/social functioning); and (5)&#xD;
      employ advanced neuroimaging techniques before and after treatment among a subset of enrolled&#xD;
      subjects. This proposal is directly responsive to the missions of the Institute for&#xD;
      Translational Neuroscience (ITN), and the US Army/Department of Defense (DoD) in that it&#xD;
      seeks to accelerate the development of new, medication-based treatments to mitigate the&#xD;
      impact of AUD and comorbid psychological conditions, such as PTSD, in the military/Veteran&#xD;
      context. The findings of this study will provide critically needed empirical evidence to help&#xD;
      inform practice guidelines and better serve the needs of U.S. service members, Veterans and&#xD;
      their families.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Alcohol Use Disorder Severity</measure>
    <time_frame>From baseline to week 8 of treatment</time_frame>
    <description>Change in Alcohol Use Disorder Severity as measured by change in average drinking days per week from baseline to week 8.&#xD;
Greater reduction in drinking days indicates better treatment outcomes. Drinking days measured over 1 week periods (7 days). Scale ranges from 0 days to 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Post Traumatic Stress Disorder Severity</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Change in post traumatic stress disorder severity as measured by Change in Clinician Administered PTSD Scale (CAPS-5) score from baseline to week 8.&#xD;
Greater change/reduction in score indicates better outcomes and greater reduction in PTSD symptomatology.&#xD;
(minimum score of 0 = absent to a maximum score of 80 = extreme)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Alcohol Craving</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Change in Alcohol craving as measured by change in Obsessive Compulsive Drinking Scale (OCDS) Total Score.&#xD;
Greater change/reduction in score indicates better outcomes and reduced alcohol craving.&#xD;
(Scores range from 0 to 56)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Post Traumatic Stress Disorder Severity</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Post traumatic stress disorder symptoms as measured by change/reduction in score of post traumatic stress disorder checklist (PCL-5) from baseline to week 8.&#xD;
Greater reduction in score indicates better treatment outcomes. (minimum score of 0 = absent to a maximum score of 80 = extreme)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Posttraumatic Stress Disorder (PTSD)</condition>
  <condition>Alcohol Use Disorder (AUD)</condition>
  <condition>Substance Use Disorder (SUD)</condition>
  <arm_group>
    <arm_group_label>NAC/CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/CBT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo pills and CBT for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>1200mg bid (2400mg/day)</description>
    <arm_group_label>NAC/CBT</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills bid</description>
    <arm_group_label>Placebo/CBT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy</intervention_name>
    <description>CBT for AUD/SUD, one hour/once a week</description>
    <arm_group_label>NAC/CBT</arm_group_label>
    <arm_group_label>Placebo/CBT</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, any race or ethnicity, age 18 to 75 years old.&#xD;
&#xD;
          -  U.S. military Veteran, including National Guard and Reservists.&#xD;
&#xD;
          -  Able to comprehend English.&#xD;
&#xD;
          -  Meet Diagnostic and Statistical Manual (DSM-5) criteria for current alcohol use&#xD;
             disorder (AUD) and/or substance use disorder (SUD).&#xD;
&#xD;
          -  Meet DSM-5 criteria for current PTSD or subthreshold PTSD. Subjects may also meet&#xD;
             criteria for a mood disorder (except bipolar affective disorder, see Exclusion&#xD;
             Criteria) or other anxiety disorders (e.g., panic disorder, agoraphobia, social&#xD;
             phobia, generalized anxiety disorder). The inclusion of subjects with affective and&#xD;
             other anxiety disorders is essential because of the marked frequency of the&#xD;
             co-existence of mood and other anxiety disorders among patients with PTSD (Brady et&#xD;
             al., 2000; Kessler et al., 2005).&#xD;
&#xD;
          -  Subjects taking psychotropic medications will be required to be maintained on a stable&#xD;
             dose for at least four weeks before treatment initiation. This is because initiation&#xD;
             or change of medications during the course of the trial may interfere with&#xD;
             interpretation of results.&#xD;
&#xD;
          -  Must consent to random assignment to N-acetylcysteine (NAC) or placebo.&#xD;
&#xD;
          -  Must consent to complete all treatment and follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting DSM-5 criteria for a history of or current psychotic or bipolar&#xD;
             affective disorders, as the study protocol may be therapeutically insufficient.&#xD;
&#xD;
          -  Subjects with a current eating disorder (bulimia, anorexia nervosa) or with&#xD;
             dissociative identity disorder, as they are likely to require specific time-intensive&#xD;
             psychotherapy.&#xD;
&#xD;
          -  Subjects experiencing significant withdrawal symptoms, as evidence by a score of 10 or&#xD;
             above on the Clinical Institute Withdrawal Assessment of Alcohol (CIWA).These subjects&#xD;
             will be referred for clinical detoxification and may be re-assessed for study&#xD;
             eligibility after medically supervised detoxification has been completed.&#xD;
&#xD;
          -  Individuals considered an immediate suicide risk based on the Columbia Suicide&#xD;
             Severity Rating Scale (C-SSRS) or who are likely to require hospitalization during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Women who are pregnant, nursing or not practicing an effective form of birth control.&#xD;
&#xD;
          -  Asthma or any clinically significant medical condition that in the opinion of the&#xD;
             investigators would adversely affect safety or study participation.&#xD;
&#xD;
          -  Use of carbamazepine, phenytoin, nitrous oxide, methotrexate, 6 azauridine triacetate,&#xD;
             or nitroglycerin within the last 14 days or any other medication felt to have a&#xD;
             hazardous interaction if taken with NAC.&#xD;
&#xD;
          -  History of childhood or adult seizures of any cause.&#xD;
&#xD;
          -  MRI exclusions: Claustrophobia; tattoos above the shoulders; permanent eyeliner or&#xD;
             permanent artificial eyebrows; cardiac pacemaker; metal fragments in eye, skin, or&#xD;
             body, including shrapnel; heart valve replacement; brain clips; venous umbrella; being&#xD;
             a sheet-metal worker or welder; lifetime history of aneurysm surgery; intracranial&#xD;
             bypass, renal, or aortic clips; prosthetic devices such as middle ear, eye, joint, or&#xD;
             penile implants; joint replacements; non-removable hearing aid, neurostimulator, or&#xD;
             insulin pump; shunts/stents; metal mesh/coil implants; metal plate/pin/screws/wires;&#xD;
             or any other metal implants. Note that individuals who meet inclusion/exclusion&#xD;
             criteria for the medication component of the study but not the MRI portion (e.g.,&#xD;
             excluded due to metal implants) will still be eligible to enroll in and complete the&#xD;
             medication/treatment phase.&#xD;
&#xD;
          -  Subjects on maintenance anxiolytic, antidepressant, or mood stabilizing medications&#xD;
             which have been initiated during the past four weeks. If it is determined, based on&#xD;
             clinical criteria, that a subject needs to be started on maintenance medications for&#xD;
             anxiety, mood or psychotic symptoms during the course of the study, they will be&#xD;
             discontinued from the treatment trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudie Back, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H Johnson VA Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <results_first_submitted>March 27, 2021</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <disposition_first_submitted>June 4, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 4, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 5, 2020</disposition_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>PTSD</keyword>
  <keyword>Trauma</keyword>
  <keyword>Veteran</keyword>
  <keyword>Substance</keyword>
  <keyword>Drug</keyword>
  <keyword>Post Traumatic Stress Disorder</keyword>
  <keyword>Military</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02911285/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02911285/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine (NAC) Plus Cognitive Behavioral Therapy (CBT)</title>
          <description>Participants randomized to N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
N-acetylcysteine: 1200mg bid (2400mg/day)&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Cognitive Behavioral Therapy (CBT)</title>
          <description>Participants received placebo pills and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
Placebo: Placebo pills bid&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant got a job and no longer had time to participate.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine + Cognitive Behavioral Therapy</title>
          <description>Participants received N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
N-acetylcysteine: 1200mg bid (2400mg/day)&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Cognitive Behavioral Therapy</title>
          <description>Participants received placebo pills and CBT for 8 weeks.&#xD;
Placebo: Placebo pills bid&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.99" spread="11.51"/>
                    <measurement group_id="B2" value="49.13" spread="13.23"/>
                    <measurement group_id="B3" value="50.85" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Data on sex collected via self-report demographic form.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Alcohol Use Disorder Severity</title>
        <description>Change in Alcohol Use Disorder Severity as measured by change in average drinking days per week from baseline to week 8.&#xD;
Greater reduction in drinking days indicates better treatment outcomes. Drinking days measured over 1 week periods (7 days). Scale ranges from 0 days to 7 days.</description>
        <time_frame>From baseline to week 8 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
N-acetylcysteine: 1200mg twice per day (2400mg/day)&#xD;
Cognitive behavioral therapy: for alcohol/substance use disorder, one hour/once a week</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received placebo pills and CBT for 8 weeks.&#xD;
Placebo: Placebo pills twice per day&#xD;
Cognitive behavioral therapy: for alcohol/substance use disorder, one hour/once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alcohol Use Disorder Severity</title>
          <description>Change in Alcohol Use Disorder Severity as measured by change in average drinking days per week from baseline to week 8.&#xD;
Greater reduction in drinking days indicates better treatment outcomes. Drinking days measured over 1 week periods (7 days). Scale ranges from 0 days to 7 days.</description>
          <units>drinking days reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="3.85"/>
                    <measurement group_id="O2" value="-2.82" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Post Traumatic Stress Disorder Severity</title>
        <description>Change in post traumatic stress disorder severity as measured by Change in Clinician Administered PTSD Scale (CAPS-5) score from baseline to week 8.&#xD;
Greater change/reduction in score indicates better outcomes and greater reduction in PTSD symptomatology.&#xD;
(minimum score of 0 = absent to a maximum score of 80 = extreme)</description>
        <time_frame>From baseline to week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
N-acetylcysteine: 1200mg bid (2400mg/day)&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received placebo pills and CBT for 8 weeks.&#xD;
Placebo: Placebo pills bid&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post Traumatic Stress Disorder Severity</title>
          <description>Change in post traumatic stress disorder severity as measured by Change in Clinician Administered PTSD Scale (CAPS-5) score from baseline to week 8.&#xD;
Greater change/reduction in score indicates better outcomes and greater reduction in PTSD symptomatology.&#xD;
(minimum score of 0 = absent to a maximum score of 80 = extreme)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.93" spread="13.42"/>
                    <measurement group_id="O2" value="-5.53" spread="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Alcohol Craving</title>
        <description>Change in Alcohol craving as measured by change in Obsessive Compulsive Drinking Scale (OCDS) Total Score.&#xD;
Greater change/reduction in score indicates better outcomes and reduced alcohol craving.&#xD;
(Scores range from 0 to 56)</description>
        <time_frame>From baseline to week 8</time_frame>
        <population>39 participants completed survey in NAC group and 37 participants completed survey in placebo group</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
N-acetylcysteine: 1200mg bid (2400mg/day)&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received placebo pills and CBT for 8 weeks.&#xD;
Placebo: Placebo pills bid&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alcohol Craving</title>
          <description>Change in Alcohol craving as measured by change in Obsessive Compulsive Drinking Scale (OCDS) Total Score.&#xD;
Greater change/reduction in score indicates better outcomes and reduced alcohol craving.&#xD;
(Scores range from 0 to 56)</description>
          <population>39 participants completed survey in NAC group and 37 participants completed survey in placebo group</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.97" spread="7.26"/>
                    <measurement group_id="O2" value="-2.92" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Post Traumatic Stress Disorder Severity</title>
        <description>Post traumatic stress disorder symptoms as measured by change/reduction in score of post traumatic stress disorder checklist (PCL-5) from baseline to week 8.&#xD;
Greater reduction in score indicates better treatment outcomes. (minimum score of 0 = absent to a maximum score of 80 = extreme)</description>
        <time_frame>From baseline to week 8</time_frame>
        <population>39 participants completed survey in NAC group, and 37 completed survey in placebo group</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
N-acetylcysteine: 1200mg twice per day (2400mg/day)&#xD;
Cognitive behavioral therapy for alcohol/substance use disorder, one hour/once a week</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cognitive Behavioral Therapy (CBT)</title>
            <description>Participants received placebo pills and CBT for 8 weeks.&#xD;
Placebo: Placebo pills twice per day&#xD;
Cognitive behavioral therapy for alcohol/substance use disorder, one hour/once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post Traumatic Stress Disorder Severity</title>
          <description>Post traumatic stress disorder symptoms as measured by change/reduction in score of post traumatic stress disorder checklist (PCL-5) from baseline to week 8.&#xD;
Greater reduction in score indicates better treatment outcomes. (minimum score of 0 = absent to a maximum score of 80 = extreme)</description>
          <population>39 participants completed survey in NAC group, and 37 completed survey in placebo group</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.97" spread="18.36"/>
                    <measurement group_id="O2" value="-9.97" spread="16.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 8-9 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT)</title>
          <description>Participants received N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.&#xD;
N-acetylcysteine: 1200mg bid (2400mg/day)&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Cognitive Behavioral Therapy (CBT)</title>
          <description>Participants received placebo pills and CBT for 8 weeks.&#xD;
Placebo: Placebo pills bid&#xD;
Cognitive behavioral therapy: CBT for AUD/SUD, one hour/once a week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Nose Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Lesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aborted Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Changes</sub_title>
                <description>Increase or decrease in appetite</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Knee Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <description>General respiratory illness (cold, cough, flu, sinus infection, congestion)</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stacey Sellers, Program Manager</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-5807</phone>
      <email>sellersst@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

